{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:24:11Z","timestamp":1765545851375},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00259-013-2493-9","type":"journal-article","created":{"date-parts":[[2013,7,15]],"date-time":"2013-07-15T12:13:34Z","timestamp":1373890414000},"page":"119-125","source":"Crossref","is-referenced-by-count":29,"title":["Comparative study of the safety of regadenoson between patients with mild\/moderate chronic obstructive pulmonary disease and asthma"],"prefix":"10.1007","volume":"41","author":[{"given":"Carlos Salgado","family":"Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia Jimenez","family":"Heffernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sanchez de Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Ramos Font","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juana","family":"Lopez Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Rivera de los Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Ynfante Mil\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,16]]},"reference":[{"key":"2493_CR1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2967\/jnmt.108.056465","volume":"36","author":"HW Strauss","year":"2008","unstructured":"Strauss HW, Miller DD, Wittry MD, Cerqueira MD, Garcia EV, Iskandrian AS, et al. Procedure guideline for myocardial perfusion imaging 3.3. J Nucl Med Technol. 2008;36:155\u201361.","journal-title":"J Nucl Med Technol"},{"key":"2493_CR2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ccd.21307","volume":"71","author":"RJ McGeoch","year":"2008","unstructured":"McGeoch RJ, Oldroyd KG. Pharmacological options for inducing maximal hyperemia during studies of coronary physiology. Catheter Cardiovasc Interv. 2008;71:198\u2013204.","journal-title":"Catheter Cardiovasc Interv"},{"key":"2493_CR3","author":"MJ Henzlova","year":"2009","unstructured":"Henzlova MJ, Cerqueira MD, Taillefer R, Mahmarian JJ, Yao SS. Quality Assurance Committee of the American Society of Nuclear Cardiology. Stress protocols and tracers. J Nucl Cardiol. 2009. doi: 10.1007\/s12350-009-9062-4 .","journal-title":"J Nucl Cardiol"},{"key":"2493_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0735-6757(93)90138-2","volume":"11","author":"KK Burkhart","year":"1993","unstructured":"Burkhart KK. Respiratory failure following adenosine administration. Am J Emerg Med. 1993;11:249\u201350.","journal-title":"Am J Emerg Med"},{"key":"2493_CR5","unstructured":"Adenoscan. Package insert. 2008. Health Ministry. Spain."},{"issue":"4","key":"2493_CR6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12350-012-9565-2","volume":"19","author":"RC Thompson","year":"2012","unstructured":"Thompson RC. Regadenoson stress in patients with asthma and COPD: a breath of fresh air. J Nucl Cardiol. 2012;19(4):647\u20138.","journal-title":"J Nucl Cardiol"},{"key":"2493_CR7","unstructured":"European Medicines Agency. Assessment report for Rapiscan. London: European Medicines Agency; 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001176\/WC500097103.pdf . Accessed 29 Jun 2013."},{"key":"2493_CR8","unstructured":"Lexiscan (Regadenoson) injection [package insert]. Deerfield: Astellas Pharma US, Inc; 2011."},{"key":"2493_CR9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11886-006-0022-1","volume":"8","author":"MD Cerqueira","year":"2006","unstructured":"Cerqueira MD. Advances in pharmacologic agents in imaging: new A2A receptor agonists. Curr Cardiol Rep. 2006;8:119\u201322.","journal-title":"Curr Cardiol Rep"},{"key":"2493_CR10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nuclcard.2008.02.009","volume":"15","author":"BR Leaker","year":"2008","unstructured":"Leaker BR, O\u2019Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol. 2008;15:329\u201336.","journal-title":"J Nucl Cardiol"},{"key":"2493_CR11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nuclcard.2008.02.013","volume":"15","author":"GS Thomas","year":"2008","unstructured":"Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol. 2008;15:319\u201328.","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"2493_CR12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12350-012-9547-4","volume":"19","author":"BM Prenner","year":"2012","unstructured":"Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol. 2012;19(4):681\u201392.","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"2493_CR13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","volume":"14","author":"AE Iskandrian","year":"2007","unstructured":"Iskandrian AE, Bateman TM, Beladinelli L, Blackburn B, Cerqueira MD, Hendel RC. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007;14(5):645\u201358.","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"2493_CR14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcmg.2008.02.003","volume":"1","author":"MD Cerqueira","year":"2008","unstructured":"Cerqueira MD, Nguyen P, Staehr S, Underwood R, Iskandrian AE; ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: integrated ADVANCE-MPI trial results. J Am Coll Cardiol Imaging. 2008;1(3):307\u201316.","journal-title":"J Am Coll Cardiol Imaging"},{"issue":"5","key":"2493_CR15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1165\/ajrcmb.16.5.9160835","volume":"16","author":"BA Walker","year":"1997","unstructured":"Walker BA, Jacobson MA, Knight DA, Salvatore CA, Weir T, Zhou D, et al. Adenosine A3 receptor expression and function in eosinophils. Am J Respir Cell Mol Biol. 1997;16(5):531\u20137.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"2493_CR16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1183\/09031936.00003707","volume":"31","author":"RA Brown","year":"2008","unstructured":"Brown RA, Clarke GW, Ledbetter CL, Hurle MJ, Denyer JC, Simcock DE, et al. Elevated expression of adenosine A1 receptor in bronchial biopsy specimens from asthmatic subjects. Eur Respir J. 2008;31(2):311\u20139.","journal-title":"Eur Respir J"},{"issue":"5","key":"2493_CR17","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1164\/ajrccm\/145.5.1087","volume":"145","author":"T Bjorck","year":"1992","unstructured":"Bjorck T, Gustafsson LE, Dahlen SE. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis. 1992;145(5):1087\u201391.","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"2493_CR18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12350-008-9001-9","volume":"16","author":"GS Thomas","year":"2009","unstructured":"Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining Regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol. 2009;16(1):63\u201372.","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"2493_CR19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12350-010-9229-z","volume":"17","author":"DH Kwon","year":"2010","unstructured":"Kwon DH, Cerqueira MD, Young R, Houghtaling P, Lieber E, Menon V, et al. Lessons from regadenoson and low-level treadmill\/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients. J Nucl Cardiol. 2010;17(5):853\u20137.","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"2493_CR20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/jpet.105.095323","volume":"316","author":"AK Dhalla","year":"2006","unstructured":"Dhalla AK, Wong M, Wang W, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonist is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316(2):695\u2013702.","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"2493_CR21","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2009.04.089","volume":"54","author":"WA Al Jaroudi","year":"2009","unstructured":"Al Jaroudi WA, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol. 2009;54(13):1123\u201330.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2493_CR22","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12350-012-9533-x","volume":"19","author":"R Doukky","year":"2012","unstructured":"Doukky R, Morales Demori R, Jain S, Kiriakos R, Mwansa V, Calvin JE. Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. \u201cThe ASSUAGE trial\u201d. J Nucl Cardiol. 2012;19(3):448\u201357.","journal-title":"J Nucl Cardiol"},{"key":"2493_CR23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12350-012-9658-y","volume":"20","author":"AE Iskandrian","year":"2013","unstructured":"Iskandrian AE, Hage FG, Heo J. Use of regadenoson in end-stage renal disease. J Nucl Cardiol. 2013;20:182\u20134.","journal-title":"J Nucl Cardiol"},{"key":"2493_CR24","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s10554-011-0003-3","volume":"28","author":"Z Husain","year":"2012","unstructured":"Husain Z, Palani G, Cabrera R, Karthikeyan AS, Dhanalakota S, Pathmanathan S, et al. Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. Int J Cardiovasc Imaging. 2012;28:1841\u20139.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"4","key":"2493_CR25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ahj.2009.01.011","volume":"157","author":"FG Hage","year":"2009","unstructured":"Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J. 2009;157(4):771\u20136.","journal-title":"Am Heart J"},{"key":"2493_CR26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4103\/0022-3859.97177","volume":"58","author":"GM Bengalorkar","year":"2012","unstructured":"Bengalorkar GM, Bhuvana K, Sarala N, Kumar TN. Regadenoson. J Postgrad Med. 2012;58:140\u20136.","journal-title":"J Postgrad Med"},{"key":"2493_CR27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00259-012-2296-4","volume":"40","author":"WA Al Jaroudi","year":"2013","unstructured":"Al Jaroudi WA, Alraies MC, Cerqueira MD, Jaber WA. Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response. Eur J Nucl Med Mol Imaging. 2013;40:341\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2493-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-013-2493-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2493-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:05:30Z","timestamp":1558699530000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-013-2493-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,16]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2493"],"URL":"https:\/\/doi.org\/10.1007\/s00259-013-2493-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,16]]}}}